Natalia Ruetalo
Overview
Explore the profile of Natalia Ruetalo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
650
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Stich M, Elling R, Renk H, Janda A, Garbade S, Muller B, et al.
Emerg Infect Dis
. 2021 Oct;
27(12):3009-3019.
PMID: 34695369
Resolving the role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in households with members from different generations is crucial for containing the current pandemic. We conducted a large-scale,...
12.
Ruetalo N, Businger R, Schindler M
Euro Surveill
. 2021 Oct;
26(42).
PMID: 34676820
Background: The COVID-19 pandemic urges for cheap, reliable, and rapid technologies for disinfection and decontamination. One frequently proposed method is ultraviolet (UV)-C irradiation. UV-C doses necessary to achieve inactivation of...
13.
Auth J, Froba M, Grosse M, Rauch P, Ruetalo N, Schindler M, et al.
Int J Mol Sci
. 2021 Oct;
22(19).
PMID: 34638545
Even in the face of global vaccination campaigns, there is still an urgent need for effective antivirals against SARS-CoV-2 and its rapidly spreading variants. Several natural compounds show potential as...
14.
Becker M, Dulovic A, Junker D, Ruetalo N, Kaiser P, Pinilla Y, et al.
Nat Commun
. 2021 May;
12(1):3109.
PMID: 34035301
SARS-CoV-2 is evolving with mutations in the receptor binding domain (RBD) being of particular concern. It is important to know how much cross-protection is offered between strains following vaccination or...
15.
Grosse M, Ruetalo N, Layer M, Hu D, Businger R, Rheber S, et al.
Viruses
. 2021 Apr;
13(4).
PMID: 33918670
While vaccination campaigns are ongoing worldwide, there is still a tremendous medical need for efficient antivirals against SARS-CoV-2 infection. Among several drug candidates, chloroquine (CQN) and hydroxychloroquine (H-CQN) were tested...
16.
Wagner T, Ostertag E, Kaiser P, Gramlich M, Ruetalo N, Junker D, et al.
EMBO Rep
. 2021 Apr;
22(5):e52325.
PMID: 33904225
In light of the COVID-19 pandemic, there is an ongoing need for diagnostic tools to monitor the immune status of large patient cohorts and the effectiveness of vaccination campaigns. Here,...
17.
Fink S, Ruoff F, Stahl A, Becker M, Kaiser P, Traenkle B, et al.
ACS Infect Dis
. 2021 Mar;
7(6):1596-1606.
PMID: 33724771
The presence of antibodies against endemic coronaviruses has been linked to disease severity after SARS-CoV-2 infection. Assays capable of concomitantly detecting antibodies against endemic coronaviridae such as OC43, 229E, NL63,...
18.
Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients
Ruetalo N, Businger R, Althaus K, Fink S, Ruoff F, Pogoda M, et al.
mSphere
. 2021 Feb;
6(1).
PMID: 33627511
The majority of infections with SARS-CoV-2 are asymptomatic or mild without the necessity of hospitalization. It is of importance to reveal if these patients develop an antibody response against SARS-CoV-2...
19.
Koenig P, Das H, Liu H, Kummerer B, Gohr F, Jenster L, et al.
Science
. 2021 Jan;
371(6530).
PMID: 33436526
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread, with devastating consequences. For passive immunization efforts, nanobodies have size and cost advantages over conventional antibodies....
20.
Flehmig B, Schindler M, Ruetalo N, Businger R, Bayer M, Haage A, et al.
Viruses
. 2020 Dec;
12(12).
PMID: 33260809
The relationship between the nasopharyngeal virus load, IgA and IgG antibodies to both the S1-RBD-protein and the N-protein, as well as the neutralizing activity (NAbs) against SARS-CoV-2 in the blood...